Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6761176 | 1.00 | CHRM2 (0.54) | CHRM2CHRM1CHRM3GPR119NAAA | |
| SCHEMBL6758133 | 1.00 | CHRM2 (0.54) | CHRM2CHRM1CHRM3GPR119NAAA | |
| SCHEMBL6758129 | 1.00 | CHRM2 (0.54) | CHRM2CHRM1CHRM3GPR119NAAA | |
| SCHEMBL16390913 | 0.90 | GPR119 (0.51) | CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL16390912 | 0.90 | GPR119 (0.51) | CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL6758165 | 0.90 | GPR119 (0.42) | CHRM2CHRM1CHRM3GPR119NAAA | |
| SCHEMBL6758163 | 0.90 | GPR119 (0.42) | CHRM2CHRM1CHRM3GPR119NAAA | |
| SCHEMBL20989256 | 0.88 | CHRM2 (0.55) | CHRM2CHRM1CHRM3GPR119NAAA | |
| SCHEMBL21526582 | 0.88 | CHRM2 (0.55) | CHRM2CHRM1CHRM3GPR119PREP | |
| SCHEMBL2099053 | 0.88 | CHRM2 (0.55) | CHRM2CHRM1CHRM3GPR119PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865194-B2 | Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2020-12-15 | — | — | US | disclosed |
| US-20190135778-A1 | THERAPEUTICALLY ACTIVE BICYCLIC-SULPHONAMIDES AND PHARMACEUTICAL COMPOSITIONS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135778-A1 | THERAPEUTICALLY ACTIVE BICYCLIC-SULPHONAMIDES AND PHARMACEUTICAL COMPOSITIONS | NAAA, FAAH, FAAH2 | CHRM2 3250/4885CHRM1 3619/4885CHRM3 3021/4885 |
| US-10865194-B2 | Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions | NAAA, FAAH2, FAAH | CHRM2 815/4885CHRM1 657/4885CHRM3 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.